Table 4.
Incidence of nephro-, haemato- and hepatotoxicity events (safety population)
| Event | From day 1 of the first LAN–PRRT cycle to the end of the last LAN–PRRT cycle (n = 31) |
From the end of the last LAN–PRRT cycle to the last available follow-up (n = 31) |
||
|---|---|---|---|---|
| N | n (%) | N | n (%) | |
| Any events | 26 | 2 (6.5) | 5 | 2 (6.5) |
| Haematotoxicity/bone marrow toxicity | 20 | 2 (6.5) | 3 | 2 (6.5) |
| Grade 1 | 12 | 2 (6.5) | 3 | 2 (6.5) |
| Grade 2 | 5 | 1 (3.2) | – | – |
| Grade 3 | 3 | 2 (6.5) | – | – |
| Hepatotoxicity | 5 | 1 (3.2) | 2 | 1 (3.2) |
| Grade 1 | 3 | 1 (3.2) | 1 | 1 (3.2) |
| Grade 2 | 2 | 1 (3.2) | – | – |
| Grade 3 | – | – | 1 | 1 (3.2) |
| Renal toxicity | 1 | 1 (3.2) | – | – |
| Grade 1 | 1 | 1 (3.2) | – | – |
LAN, lanreotide autogel/depot; n, number of patients; N, number of events; PRRT, peptide receptor radionuclide therapy